• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Freitag Gregory Gene

    7/15/25 4:22:57 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVSA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Freitag Gregory Gene

    (Last) (First) (Middle)
    C/O ZYVERSA THERAPEUTICS, INC.
    2200 N. COMMERCE PARKWAY, SUITE 208

    (Street)
    WESTON FL 26333

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ZyVersa Therapeutics, Inc. [ ZVSA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $0.59 07/11/2025 A 11,066 (1) 07/11/2035 Common Stock 11,066 $0 11,066 D
    Explanation of Responses:
    1. The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.
    /s/ Stephen C. Glover as Attorney-in-Fact for Gregory Freitag pursuant to Power of Attorney 07/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ZVSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZVSA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ZyVersa Therapeutics Inc.

    SCHEDULE 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    8/14/25 9:25:43 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ZyVersa Therapeutics Inc.

    10-Q - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    8/13/25 8:55:58 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ZyVersa Therapeutics Inc.

    EFFECT - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    8/7/25 12:15:17 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

    KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIR

    8/13/25 9:00:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

    WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa")), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a mid-year Shareholder Letter to update investors on recent corporate developments and to highlight near-term value-building R&D milestones for second half of 2025. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Shareholders: Over my 40-year career, I've seen the full a

    7/21/25 7:55:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

    WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa")), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the "Series A-2 Warrants") and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the "Series A-3 Warrants," and together with the Serie

    7/8/25 12:30:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Commercial Officer Cashmere Karen A.

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    7/16/25 12:55:04 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Finizio Robert G

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    7/15/25 4:22:54 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Glover Stephen C.

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    7/15/25 4:22:55 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Financials

    Live finance-specific insights

    View All

    ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

    KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIR

    8/13/25 9:00:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

    KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects at risk of cardiometabolic diseases.Groundbreaking data demonstrating IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation — bot

    5/12/25 4:35:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

    KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative). Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation

    3/27/25 9:15:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care